Surmodics (SRDX)
(Delayed Data from NSDQ)
$37.66 USD
+0.09 (0.24%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $37.66 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
SRDX 37.66 +0.09(0.24%)
Will SRDX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRDX
ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates
SRDX Stock Down Despite FDA Clearance for Pounce XL System
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for SRDX
Beryl Capital Management LLC Acquires New Stake in Profire Energy Inc
Surmodics receives FDA clearance for its thrombectomy system
Surmodics Receives FDA 510(k) Clearance for Pounce? XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
FDA gives Surmodics clearance for Pounce XL Thrombectomy System
Beryl Capital Management LLC Acquires New Stake in Revance Therapeutics Inc